Evidence map›Paper›PMID 33219985›Full record

ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2020

Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease.

Amandeep Singh, Rajat Garg, Nan Lan, Mohamed Tausif Siddiqui, Mohit Gupta, Naim Alkhouri

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Editorial commentary on the Indian Journal of Gastroenterology November-December 2020.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amandeep Singh *Department of Gastroenterology, Hepatology and Center for Human Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, A5 Annex, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. Singha4@ccf.org.
Rajat Garg *Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-1343-9939
Nan LanDepartment of Gastroenterology, Hepatology and Center for Human Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, A5 Annex, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Mohamed Tausif SiddiquiDepartment of Gastroenterology, Hepatology and Center for Human Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, A5 Annex, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Mohit GuptaDepartment of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
Naim AlkhouriTexas Liver Institute, University of San Antonio, San Antonio, TX, USA.
Cleveland Clinic · USTexas Liver Institute · US

Funding

Combined Training Program in Digestive Disease SciencesT32DK083251 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI COMINELLI, FABIO, FIOCCHI, CLAUDIO · 2010 to 2025
$3.6M
Training Program in Academic GastroenterologyT32DK061917 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, GREGORY S. · 2002 to 2006
$795k
NIDDK NIH HHS T32 DK061917NIDDK NIH HHS T32 DK083251
6 · The paper itself

Abstract

BACKGROUNDS AND

aimsData on associations of antacid therapies with advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD) are limited. We aimed to assess the association of histamine-2 receptor antagonists (H

methodsWe retrospectively reviewed patient's charts with T2D who had a liver biopsy for suspected NAFLD. Fibrosis stages were determined as F0-F4, AF being F3-4. Laboratory data and use of various medications within 24 months of liver biopsies were used for the analysis. Univariable and multivariable logistic regression analyses were performed to assess any association.

resultsOur cohort consisted of 1008 T2D patients with biopsy-proven NAFLD. Sixty-six percent were female, 86.2% were Caucasian, and median HbA

conclusionOur study suggests that H

Indexed as

BiopsyDiabetes Mellitus, Type 2FemaleFibrosisHistamine H2 AntagonistsHumansLiverMaleNon-alcoholic Fatty Liver DiseaseProton Pump InhibitorsRetrospective StudiesRiskHistamine H2 AntagonistsProton Pump InhibitorsAdvanced fibrosisCryptogenic cirrhosisFatty liverInsulin resistanceMetabolic syndromeProton pump inhibitorsSteatohepatitisType-2 diabetics

Identifiers

PMID33219985
PMCPMC9254737
OpenAlexW3098615719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.